Laura Lee Sandler, serving as the Chief Operating Officer for Oruka Therapeutics, Inc. (NASDAQ: ORKA), executed a sale of the company's common stock on June 15, 2026. The total value of the transaction amounted to $41,814. This sale involved the disposition of 600 shares at a per-share price of $69.69. Following the completion of this transaction, Ms. Sandler maintains direct ownership of 236,384 shares of Oruka Therapeutics common stock.
The reported sale was processed in accordance with Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure. This specific mechanism is utilized to satisfy tax withholding obligations that arise in connection with the vesting of restricted stock units.
Oruka Therapeutics has recently announced positive interim results from its EVERLAST-A Phase 2a trial. The trial focused on ORKA-001 for the treatment of moderate-to-severe plaque psoriasis. The data revealed that 63.5% of participants achieved complete skin clearance at Week 16. Significant secondary endpoint achievements were also reported.
Following the announcement of the trial results, H.C. Wainwright raised its price target for Oruka Therapeutics to $120. The firm maintained a Buy rating for the stock. Piper Sandler also reaffirmed an Overweight rating with a $180 price target. This update followed Oruka's amendment of its licensing agreement with Paragon Therapeutics. The amendment allows for expanded development opportunities in previously restricted areas.
Oruka Therapeutics also priced a $700 million stock offering at $72.50 per share. The company expects to use the proceeds for general corporate purposes. The funds may also be directed toward further clinical developments. These developments occur as analysts continue to show confidence in Oruka's future prospects.
Recent market activity for Oruka Therapeutics reflects a closing price of $68.86, representing a decrease of $1.03 or -1.47%. The stock showed a change of 0.000 or 0.00% in after-hours trading at 16:10:05 USD.